SCHEMBL16149249

SCHEMBL16149249

COC(=O)c1ccnc2cc(-c3ccc(OC)cc3C)[nH]c12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 11/20 0.81
KDM5A P29375 8/20 0.81
KDM5B Q9UGL1 7/20 0.81
LMNA P02545 1/20 0.43
KDM4E B2RXH2 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KDM4A O75164 2/20 0.43
DRD1 P21728 1/20 0.39
TLR8 Q9NR97 1/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16149595 0.90 KDM4C (1.00) KDM4CKDM5AKDM5BLMNAKDM4A
SCHEMBL20125301 0.79 KDM4C (0.67) KDM4CKDM5AKDM5BLMNAKDM4E
SCHEMBL20125364 0.78 KDM4C (0.65) KDM4CKDM5AKDM5BKDM4ECYP1A2
SCHEMBL17610152 0.77 KDM4C (0.83) KDM4CKDM5AKDM5BLMNA
SCHEMBL20125325 0.74 KDM4C (0.60) KDM4CKDM5AKDM5BLMNAKDM4E
SCHEMBL16149587 0.72 KDM5A (1.00) KDM4CKDM5AKDM5BKDM4A
SCHEMBL26768656 0.72 KDM4E (0.69) KDM4CKDM5AKDM5BKDM4ECYP1A2
SCHEMBL16149972 0.71 KDM4C (0.79) KDM4CKDM5AKDM5BKDM4A
SCHEMBL16150653 0.71 KDM5B (0.82) KDM4CKDM5AKDM5BKDM4A
SCHEMBL16149862 0.71 KDM5A (0.71) KDM4CKDM5AKDM5BKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190092771-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2019-03-28 US disclosed
US-20190092771-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2019-03-28 US disclosed
US-10174026-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-01-08 US disclosed
US-10174026-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-01-08 US disclosed
EP-2968282-B1 HISTONE DEMENTHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2018-05-09 EP disclosed
EP-2968282-B1 HISTONE DEMENTHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2018-05-09 EP disclosed
US-20180105521-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-04-19 US disclosed
US-20180105521-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-04-19 US disclosed
US-9873697-B2 Histone demethylase inhibitors Celgene Quantical Research, Inc. (US) 2018-01-23 US disclosed
US-9873697-B2 Histone demethylase inhibitors Celgene Quantical Research, Inc. (US) 2018-01-23 US disclosed
US-20170313702-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-11-02 US disclosed
US-20170313702-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-11-02 US disclosed
US-9738637-B2 Histone demethylase inhibitors Celgene Quantical Research, Inc. (US) 2017-08-22 US disclosed
US-9738637-B2 Histone demethylase inhibitors Celgene Quantical Research, Inc. (US) 2017-08-22 US disclosed
US-20160194315-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC 2016-07-07 US disclosed
US-20160194315-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC 2016-07-07 US disclosed
EP-2968282-A1 HISTONE DEMENTHYLASE INHIBITORS Quanticel Pharmaceuticals Inc (US) 2016-01-20 EP disclosed
WO-2014164708-A1 HISTONE DEMENTHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-10-09 WO disclosed
WO-2014164708-A1 HISTONE DEMENTHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313702-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A KDM4C 12/4885KDM5A 3/4885KDM5B 6/4885
US-20190092771-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A KDM4C 12/4885KDM5A 3/4885KDM5B 6/4885
US-20180105521-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A KDM4C 12/4885KDM5A 3/4885KDM5B 6/4885
US-20160194315-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A KDM4C 12/4885KDM5A 3/4885KDM5B 6/4885
US-10174026-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5A KDM4C 12/4885KDM5A 3/4885KDM5B 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.